<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013934</url>
  </required_header>
  <id_info>
    <org_study_id>PAB/011013</org_study_id>
    <nct_id>NCT02013934</nct_id>
  </id_info>
  <brief_title>Probiotics in Prevention of Common Cold</brief_title>
  <official_title>Benefit and Tolerability of a Probiotic Product in Subjects With Increased Susceptibility to Common Cold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probi AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probi AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the benefit and tolerability of a probiotic product&#xD;
      in subjects with increased susceptibility to common cold.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">May 17, 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of cold symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Severity of cold symptoms based on the questionnaire WURSS-21 during the cold episodes throughout the study period, in comparison between verum and placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of common cold episodes</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">899</enrollment>
  <condition>Viral Infections of the Upper Respiratory Tract</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males and females&#xD;
&#xD;
          -  age 18-70 years&#xD;
&#xD;
          -  increased risk for common cold (at least 4 episodes within 12 months)&#xD;
&#xD;
          -  commitment to adhere to former diet and physical activity&#xD;
&#xD;
          -  commitment not to use any products that may influence the study outcome (e.g. immune&#xD;
             suppressants/immune stimulants, including paramedication such as e.g. Echinacea,&#xD;
             analgesics/anti-rheumatics, anti-phlogistics, antitussives/expectorants, influenza&#xD;
             remedies, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic&#xD;
             drugs, probiotics) during the study (except for rescue medication, see 7.5)&#xD;
&#xD;
          -  women of child-bearing potential have to agree to use appropriate birth control&#xD;
             methods Written consent of the subject to participate is a prerequisite for study&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute / chronic upper / lower airways disease&#xD;
&#xD;
          -  chronic cough of any origin&#xD;
&#xD;
          -  any allergic reaction that may influence the study outcome (e.g. acute/chronic&#xD;
             rhinitis)&#xD;
&#xD;
          -  history of nasal reconstructive surgery&#xD;
&#xD;
          -  presence of nasal ulcers or nasal polyps&#xD;
&#xD;
          -  severe nasal septum deviation or other condition that could cause nasal obstruction&#xD;
&#xD;
          -  congenital or acquired immunodeficiency disease (e.g. HIV infection)&#xD;
&#xD;
          -  Bechterew's disease&#xD;
&#xD;
          -  body temperature above 37.5Â°C&#xD;
&#xD;
          -  suspected swine flu or influenza&#xD;
&#xD;
          -  vaccination with a vaccine containing an adjuvant within 3 months prior to study start&#xD;
             and during the study&#xD;
&#xD;
          -  vaccination with a vaccine not containing an adjuvant within 6 weeks prior to study&#xD;
             start and during the study&#xD;
&#xD;
          -  stomach/gastrointestinal diseases&#xD;
&#xD;
          -  serious organ or systemic diseases&#xD;
&#xD;
          -  sleep disorder&#xD;
&#xD;
          -  psychiatric disorders&#xD;
&#xD;
          -  known sensitivity to the ingredients of the investigational product&#xD;
&#xD;
          -  regular intake of products that may influence the study outcome (e.g. immune&#xD;
             suppressants/immune stimulants, including paramedication such as e.g. Echinacea,&#xD;
             analgesics/anti-rheumatics, anti-phlogistics, antitussives/expectorants, influenza&#xD;
             remedies, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic&#xD;
             drugs, probiotics) within the last 4 weeks prior to study start&#xD;
&#xD;
          -  habitual usage of nasal drops/spray&#xD;
&#xD;
          -  pregnancy or nursing&#xD;
&#xD;
          -  alcohol / drug abuse&#xD;
&#xD;
          -  simultaneous participation in another clinical trial or participation in a clinical&#xD;
             trial within the last 30 days&#xD;
&#xD;
          -  insufficient compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>A&amp;R</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

